SOLV Solventum

FY2024 10-K
Filed: Feb 28, 2025
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR

Solventum (SOLV) filed its fiscal year 2024 10-K annual report with the SEC on Feb 28, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2024 10-K

Business Overview

  • Core business model pivot implied by separation from 3M Company via Separation and Distribution Agreement dated March 31, 2024
  • Introduction of multiple transition agreements with 3M supporting independent operations post-separation
+3 more insights

Management Discussion & Analysis

  • Revenue for fiscal year 2025 not explicitly stated, no YoY dollar change disclosed
  • No specific profitability or operating margin percentages provided
+3 more insights

Risk Factors

  • Regulatory/legal risk: Ongoing impact of 3M Spin-Off-related costs, including profit mark-ups on transition service agreements and separation expenses
  • Geopolitical/macroeconomic risk: Foreign currency transaction effects and hedging reduced pre-tax income by approx. $23 million in 2024
+3 more insights

Financial Summary
XBRL

Revenue

$8.3B

Net Income

$479M

Gross Margin

55.6%

Operating Margin

12.6%

Net Margin

5.8%

ROE

16.2%

Total Assets

$14.5B

EPS (Diluted)

$2.76

Operating Cash Flow

$1.2B

Source: XBRL data from Solventum FY2024 10-K filing on SEC EDGAR. All figures in USD.

Other Solventum Annual Reports

Get deeper insights on Solventum

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available